These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28004361)

  • 1. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
    Luan C; Chen B
    Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on obinutuzumab in the treatment of B-cell malignancies.
    Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
    Said R; Tsimberidou AM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
    Klein C; Jamois C; Nielsen T
    Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
    Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
    Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
    Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
    Front Immunol; 2020; 11():584509. PubMed ID: 33329558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.